XML 22 R11.htm IDEA: XBRL DOCUMENT
v3.26.1

LIQUIDITY AND OTHER UNCERTAINTIES | 9 Months Ended
--- | ---
Jan. 31, 2026
Liquidity And Other Uncertainties |
LIQUIDITY AND OTHER UNCERTAINTIES | NOTE 2 – LIQUIDITY AND OTHER UNCERTAINTIES As of January 31, 2026, the Company had approximately $20.2 million in cash and cash equivalents as compared to approximately $15.2 million at April 30, 2025. The Company expects that its current cash and cash equivalents of approximately $19 million, as of the filing of this Quarterly Report on Form 10-Q, will be sufficient to support its projected operating requirements and financial commitments for at least the next twelve months from the date of this Quarterly Report. In August 2025, the Company entered into a securities purchase agreement pursuant to which it agreed to sell to investors in a private placement an aggregate of 7,000 shares of the Company’s newly designated Series C convertible preferred stock with a stated value of $1,000 per share and warrants to purchase up to 7 million shares of common stock, resulting in aggregate gross proceeds of $7 million. See Note 10 - Preferred stock. In September 2025, the Company entered into a securities purchase agreement pursuant to which it agreed to purchase in a private placement QCLS Series H Preferred Stock (as defined herein) initially convertible into 600,000 shares, subject to adjustment of QCLS (as defined herein) common stock and warrants for an aggregate purchase price of $3 million. See Note 4 - Investment in debt and equity securities. The Company expects to need additional capital in order to complete a clinical trial for the treatment of pancreatic cancer. If any additional equity financing, if available, may not be on favorable terms and would likely be significantly dilutive to the Company’s current stockholders and debt financing, if available, may involve restrictive covenants. If the Company is able to access funds through collaborative or licensing arrangements, it may be required to relinquish rights to some of its product candidates that the Company would otherwise seek to develop or commercialize on its own, on terms that are not favorable to the Company. The Company’s ability to access capital is not assured and, if not achieved on a timely basis, will likely have a material adverse effect on the Company’s business, financial condition and results of operations. The Company operates in an industry that is subject to rapid technological change, competition and government regulation. The Company’s operations are subject to significant risk and uncertainties including financial operational, technological, regulatory, and other risks. Such factors, include but not limited to, results of clinical testing and trial activities, the ability to obtain regulatory approval, the supply of needed materials, the ability to obtain manufacturing and the ability to raise capital to achieve strategic objectives.

X
- References No definition available. + Details
Name: | PMCB_DisclosureLiquidityAndOtherUncertaintiesAbstract
Namespace Prefix: | PMCB_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | PMCB_LiquidityAndOtherUncertainitiesTextBlock
Namespace Prefix: | PMCB_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration